CPH · STRAP.CO
Strategic Partners A/S
DKK 605.00-DKK 30.00 (-4.72%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 36.05% below the high.
Loading market information…
OTC · PARD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Poniard Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Poniard Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:18 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2008 |
|---|
| Oct 30, 2008 |
| -$14.40+2.7% vs estimate |
| $0.00 |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 605.00-DKK 30.00 (-4.72%)
Strategic Partners A/S’s quoted price sits in the lower half of its reported 52-week range, 36.05% below the high.
$0.00+$0.00 (0.0%)
PaxMedica, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 96.5% below the high.
$0.00$0.00 (0.0%)
Scopus BioPharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.0% below the high.
$0.00$0.00 (0.0%)
Regenicin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.99% below the high.
$0.00$0.00 (0.0%)
Aeolus Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
VioQuest Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00-$0.00 (0.0%)
Q BioMed Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.6% below the high.
$0.00-$0.03 (-99.63%)
Vaxxinity, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.95% below the high.
